Fourth Quarter Revenue was $662.5 million, a 27.4% increase over the prior year period Fourth Quarter Net income was $178.8 million compared to $29.2 million for the prior year period Adjusted EBITDA for Q4 2025 was $85.0 million, a 54.0% increase over the prior year period Maintained Full Year 2026 Revenue guidance of between $2.54 and $2.56 billionMaintained Full Year 2026 Adjusted EBITDA guidance of between $318 and $322 millionAnnounced agreement to acquire Family First Homecare subsequent to the Fourth QuarterATLANTA, March 19, 2026 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial results for the three-month period and fiscal year ended January 3, 2026. Jeff...

2025 closed with exceptional order momentum: Q4 2025 Order Intake increased 46% vs Q4 2024 and Order Backlog reached a multi-year record of over $1.2b, positioning the Group for significant growth in 2026, driven by new product launches, expanded North America locations and Europe dealer coverage Q4 2025 Net Sales increased to $528m, an increase of 6% vs Q4 2024; Full Year 2025 Net Sales of $1,907m, +2% vs Full Year 2024 Adjusted EBITDA grew to $48.1m in Q4 2025, representing a 9.1% Adjusted EBITDA margin, an increase of 31%, or ~170 bps, vs Q4 2024; Full Year 2025 Adjusted EBITDA of $156.0m, +13% vs Full Year 2024 Q4 2025 Net income rose to $8.8m, an increase of $2.7m vs Q4 2024 2026 Financial Guidance includes Net Sales of $1.95b to $2.15b, Adjusted EBITDA of $175m to $195m, and leverage at year-end 2026 below or equal to 2.0x.FRAUENFELD,...

Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous endometrial cancer (EC) Late-breaking oral presentation and corporate KOL panel at ESGO 2026 highlighted strong ACR-368 data in serous EC, a high unmet need subtype responsible for ~50% of EC mortality Initiated Arm 3 (ACR-368 + ultra low-dose gemcitabine) and adding Arm 4 (ACR-368) Phase 2b cohorts in all-comer (biopsy-independent) serous EC subjects Initial Phase 1 ACR-2316 data in AP3-prioritized solid tumor types showed favorable tolerability and promising clinical activity, notably in heavily pre-treated lung cancer subjects Cash, cash equivalents and marketable securities of $118.6 million as of December 31, 2025, expected to fund operations into the second quarter of 2027 WATERTOWN, Mass.,...

Conference call will be held today, Thursday, March 19 at 9:00 am ET CARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter period and full year ended December 31, 2025. 4Q25 Financial HighlightsRevenues increased 27% year over year to $968 thousand in 4Q25. Operating loss increased 17% year over year, primarily due to higher selling expenses directly related to increased sales volume and compensation expenses to facilitate growth.   Cash balance was $5.0 million as of December 31, 2025.FY2025 Financial HighlightsRevenues for FY2025 increased 33% year over year to $3.6 million. Operating...

– Achieves $206 Million Cumulative Inventory Reduction in Fiscal 2026, Surpassing Target of $150 Million – – Introduces Fiscal 2027 Modeling Assumptions – WEST FARGO, N.D., March 19, 2026 (GLOBE NEWSWIRE) — Titan Machinery Inc. (Nasdaq: TITN), (“Titan Machinery” or the “Company”), a leading network of full-service agricultural and construction equipment stores, today reported financial results for the fiscal fourth quarter and full year ended January 31, 2026. “Our fiscal 2026 results represent a year of decisive execution on our inventory reduction initiative. For the full fiscal year, we reduced total inventory by $206 million, significantly exceeding our target of $150 million — and we did it while delivering stronger-than-anticipated equipment margins. That combination is...

Company to host enhanced first quarter fiscal 2026 results conference call in June providing multi-year financial framework post closing of the joint venture transaction with WHP Global Fourth Quarter Net revenue increased 4.7% compared to the prior year Fourth Quarter GMV increased mid-single digits compared to the prior year DODGEVILLE, Wis., March 19, 2026 (GLOBE NEWSWIRE) — Lands’ End, Inc. (NASDAQ: LE) (“Lands’ End” or the “Company”) today announced financial results for the fourth quarter and full year of fiscal 2025 ended January 30, 2026. Andrew McLean, Chief Executive Officer, stated, “The fourth quarter was a turning point for Lands’ End as we returned to topline growth, driven by our most significant businesses, and capped off a year in which we strengthened the foundation for sustainable, profitable, long-term growth.” McLean...

ZELSUVMI™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total revenue including licensing revenue was $16.8 million for 2025. 8,948 ZELSUVMI units prescribed by 2,712 unique prescribers for fiscal year 2025, with a 129% quarter over quarter increase in units dispensed, rising from 2,716 units in the third quarter of 2025 to 6,232 units in the fourth quarter of 2025. Management will host a conference call today at 8:00 a.m. EDT DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos” or the “Company”), today...

CALGARY, Alberta, March 19, 2026 (GLOBE NEWSWIRE) — Calfrac Well Services Ltd. (“Calfrac” or “the Company”) (TSX: CFW) announces its financial and operating results for the three months and year ended December 31, 2025. The following press release should be read in conjunction with the management’s discussion and analysis and annual consolidated financial statements and notes thereto as at December 31, 2025. Readers should also refer to the “Forward-looking statements” legal advisory and the section regarding “Non-GAAP Measures” at the end of this press release. All financial amounts and measures are expressed in Canadian dollars unless otherwise indicated. Additional information about Calfrac is available on the SEDAR+ website at www.sedarplus.ca, including the Company’s Annual Information Form for the year ended December 31, 2025. CEO’S...

Souped-Up SweatsBy Duluth Trading CompanyFourth quarter 2025 Net Income of $7.8 million improves by $13.4 million versus prior year Fourth quarter 2025 Gross Margin of 53.0% increases by 890 basis points versus prior year Year-end inventory down 21.1% and full year positive Free Cash Flow of $16.6 million MOUNT HOREB, Wis., March 19, 2026 (GLOBE NEWSWIRE) — Duluth Holdings Inc. (dba, Duluth Trading Company) (“Duluth Trading” or the “Company”) (NASDAQ: DLTH), a lifestyle brand of men’s and women’s workwear, casual wear, outdoor apparel and accessories, today announced its financial results for the fiscal Fourth Quarter ended February 1, 2026. Summary of the Fourth Quarter ended February 1, 2026Net Income of $7.8 million compared to net loss of $5.6 million in the prior year fourth quarter. Reported EPS of $0.22; and adjusted...

BEIJING, March 19, 2026 (GLOBE NEWSWIRE) — Sunlands Technology Group (NYSE: STG) (“Sunlands” or the “Company”), a leader in China’s adult online education market and China’s adult personal interest learning market, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial and Operational SnapshotsNet revenues were RMB470.2 million (US$67.2 million), compared to RMB483.5 million in the fourth quarter of 2024. Gross billings (non-GAAP) were RMB305.7 million (US$43.7 million), compared to RMB412.4 million in the fourth quarter of 2024. Gross profit was RMB408.1 million (US$58.4 million), compared to RMB401.8 million in the fourth quarter of 2024. Net income was RMB38.4 million (US$5.5 million), compared to RMB57.8 million in the fourth quarter of 2024. Net...